Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03646162 · ClinicalTrials.gov registry record · Phase 2
Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
A Phase 2 study, sponsored by Veru.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT03646162: Completed Phase 2 study, sponsored by Veru.
NCT03646162 is a Phase 2 study that has completed, run by Veru. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03646162, a Phase 2 study, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
Primary Outcome
Percentage of change in frequency of moderate to severe hot flashes at 6 weeks
Interventions
- DRUG Placebo
- DRUG Veru-944
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 2 |
What the finished NCT03646162 record still lists
NCT03646162 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03646162 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03646162 about?
NCT03646162 is a clinical study titled "Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer". Randomized, double-blind, placebo controlled, dose finding Phase 2 study comparing oral daily dosing of VERU-944 after a week of loading (daily dosing) with placebo to ameliorate the vasomotor symptoms resulting from androgen deprivation therapy in men with advanced prostate cancer
What is the current status of trial NCT03646162?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2018-09-14. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT03646162?
The interventions under investigation include: Placebo (DRUG), Veru-944 (DRUG).
Who is sponsoring clinical trial NCT03646162?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03646162's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI